PX1 Research provides reference-grade CJC-1295 & Ipamorelin peptide blends manufactured in US-based GMP-compliant facilities for advanced laboratory research. Each lot undergoes rigorous third-party ISO 17025 testing including RP-HPLC purity verification, mass spectrometry identification, and low-level endotoxin testing to support reliable preclinical outcomes.
PX1 Research provides reference-grade CJC-1295 & Ipamorelin peptide blends manufactured in US-based GMP-compliant facilities for advanced laboratory research. Each lot undergoes rigorous third-party ISO 17025 testing including RP-HPLC purity verification, mass spectrometry identification, and low-level endotoxin testing to support reliable preclinical outcomes.
To buy CJC-1295 & Ipamorelin blend for laboratory research, qualified investigators require analytical-grade compounds with verified identity, sequence purity, and non-detectable endotoxin levels. PX1 Research supplies US-manufactured CJC-1295 (No DAC) and Ipamorelin lyophilized blends formulated specifically for in vitro assays and animal models. Every batch includes lot-specific, third-party COAs featuring HPLC and mass spectrometry data.
When purchasing dual-action growth hormone secretagogue research materials, maintaining strict batch-to-batch consistency is essential for reproducible signaling assays. Researchers can evaluate our full catalog of research compounds by visiting our all peptides hub or view detailed specifications directly on the CJC-1295 & Ipamorelin blend product page.
CJC-1295 (also known as Modified GRF 1-29) is a synthetic 29-amino-acid peptide analog of human growth hormone-releasing hormone (GHRH). By substituting specific amino acids at positions 2, 8, 15, and 27, the molecule exhibits enhanced enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) degradation in vitro compared to native GHRH(1-29). As a long-acting GHRH receptor agonist, CJC-1295 binds to the GHRH receptor on anterior pituitary somatotrophs, activating the adenylate cyclase/cAMP signaling pathway to stimulate endogenous growth hormone synthesis and release.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a highly selective agonist at the growth hormone secretagogue receptor (GHSR-1a), commonly referred to as the ghrelin receptor. Unlike first-generation GHRPs like GHRP-6 or GHRP-2, Ipamorelin demonstrates exceptional selectivity for GHSR-1a without causing significant off-target elevations of ACTH, cortisol, prolactin, or aldosterone in animal models.
When combined in a fixed laboratory ratio, CJC-1295 and Ipamorelin target two distinct, complementary cell surface receptors. To explore the structural modifications of GHRH variants in greater detail, consult our dedicated article on CJC-1295 DAC vs. No DAC mechanisms.
In somatotropic research, combining a GHRH analog with a ghrelin receptor agonist produces a synergistic amplification of growth hormone (GH) pulse amplitude rather than a simple additive effect. Preclinical literature demonstrates that simultaneous activation of GHRH receptors (Gαs-coupled) and GHSR-1a (Gαq-coupled) leads to convergent intracellular cascades.
GHRH receptor activation increases intracellular cyclic AMP (cAMP) via protein kinase A (PKA) pathways, facilitating transcription and storage of GH within pituitary vesicles. Concurrently, GHSR-1a stimulation by Ipamorelin triggers phospholipase C (PLC) activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 promotes the rapid release of intracellular calcium (Ca2+) from the endoplasmic reticulum, which drives the exocytosis of stored GH granules.
Furthermore, preclinical studies indicate that ghrelin receptor activation suppresses endogenous somatostatin (growth hormone-inhibiting hormone) signaling at the pituitary node. By simultaneously providing a strong secretagogue signal (CJC-1295) and disabling the somatostatinergic brake (Ipamorelin), the blend induces robust, physiological GH pulses in animal models. Researchers interested in receptor-binding kinetics can review our deep dive into Ipamorelin receptor selectivity and signaling.
In vivo rodent models evaluating GHRH and GHRP co-administration consistently demonstrate elevated serum GH peaks within 15 to 30 minutes post-administration. Importantly, because CJC-1295 (No DAC) maintains a half-life of approximately 30 minutes in plasma, the resulting GH release mirrors natural physiological pulsatility rather than continuous baseline elevation.
Systemic GH pulses act directly on hepatic somatotroph receptors to stimulate the transcription and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 serves as the primary downstream mediator for systemic growth, nitrogen retention, and cellular proliferation. In preclinical trials, repeated pulse stimulation via CJC-1295 and Ipamorelin results in sustained 24-hour IGF-1 bioavailability without downregulating somatotroph receptor sensitivity or blunting pituitary responsiveness over prolonged study windows.
Because the CJC-1295 & Ipamorelin combination preserves physiological feedback loops, serum IGF-1 levels rise in a controlled, dose-dependent manner in preclinical research subjects, making it an ideal candidate model for endocrine signaling studies.
In laboratory research settings, the CJC-1295 & Ipamorelin blend is widely studied for its downstream effects on cellular repair, protein synthesis, and lipid metabolism. Researchers utilize this co-formulation to explore multi-system physiological responses in vitro and in animal models:
1. **Musculoskeletal & Connective Tissue Repair:** IGF-1 signaling downstream of GH secretion promotes collagen synthesis, chondrocyte proliferation, and satellite cell activation in skeletal muscle tissue assays. Preclinical models of tendon rupture, osteotomy, and muscle strain show accelerated matrix deposition when treated with GHRH/GHRP combinations.
2. **Adipocyte & Metabolic Homeostasis:** Elevated GH concentrations enhance lipolysis via activation of hormone-sensitive lipase (HSL) while inhibiting lipoprotein lipase (LPL) activity in white adipose tissue. Rodent assays demonstrate reductions in visceral fat mass and improvements in basal metabolic indicators during high-fat diet challenges.
3. **Cellular Survival and Nitrogen Balance:** In vitro cultured cell lines subjected to oxidative stress or hypoxia demonstrate improved cell viability when exposed to IGF-1 mediated signaling cascades. To cross-reference alternative secretagogue platforms used in metabolic research, visit our overview of growth hormone secretagogues in scientific literature.
When designing somatotropic research trials, choosing the appropriate secretagogue profile depends on the target receptor class and desired pharmacokinetics. Below is a comparative overview of common laboratory compounds in this class:
CJC-1295 (No DAC) offers modified peptide stability with a 30-minute plasma half-life targeting GHRH receptors. Tesamorelin features a trans-3-hexenoic acid modification attached to GHRH(1-44), optimizing hepatic lipid clearance pathways in metabolic research. Sermorelin represents the core 29-amino-acid active sequence of endogenous GHRH, possessing a shorter half-life (10–12 minutes) best suited for rapid, acute pulse dynamics. Combining CJC-1295 with Ipamorelin yields dual GHRH/GHSR-1a receptor co-activation, delivering greater GH release per concentration than single-agent administration.
The integrity of preclinical peptide research depends entirely on compound purity and freedom from chemical contaminants. Substandard research materials containing residual trifluoroacetic acid (TFA), deletion sequences, or bacterial endotoxins introduce confounding variables that invalidate assay data.
At PX1 Research, every production batch of CJC-1295 & Ipamorelin blend undergoes exhaustive testing at independent, ISO 17025 accredited analytical laboratories in the USA. Quality assurance steps include:
**Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC):** Verifies that peptide purity meets or exceeds 98.0%, quantifying and limiting trace synthesis impurities or deletion peptides.
**Electrospray Ionization Mass Spectrometry (ESI-MS):** Confirms exact molecular mass match for both CJC-1295 and Ipamorelin within the blended matrix, ruling out structural degradation or incorrect sequence assembly.
**Limulus Amebocyte Lysate (LAL) Endotoxin Testing:** Ensures endotoxin levels remain below strictly monitored limits (<0.01 EU/mg), preventing inflammatory or cytokine spikes in cell culture and animal studies.
Every vial is labeled with a unique lot number corresponding to a publicly available, downloadable Certificate of Analysis (COA). Principal investigators requiring custom purity levels or high-volume orders for multi-center research can submit requests through our wholesale laboratory portal.
Proper handling and storage of lyophilized peptide blends are mandatory to maintain chemical stability and prevent enzymatic or physical degradation during laboratory workflow.
**Lyophilized Storage:** Store unopened vials of CJC-1295 & Ipamorelin blend at -20°C to -80°C in a desiccated environment. Under sub-zero storage conditions, the dry peptide cake remains stable for up to 24 months.
**Reconstitution Procedure:** Allow the vial to equilibrate to room temperature prior to reconstitution to minimize condensation. Reconstitute under a laminar flow hood using Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Normal Saline depending on trial parameters. Direct the solvent down the glass wall of the vial rather than shooting directly onto the lyophilized cake. Gently swirl the vial until dissolved; avoid vigorous shaking, which induces shear stress and peptide aggregation.
**Reconstituted Stability:** Following reconstitution, store liquid solutions at 2°C to 8°C. Bacteriostatic formulations remain stable for up to 30 days under refrigeration. Aliquoting reconstitutions into single-use microcentrifuge tubes prior to freezing (-80°C) prevents repeated freeze-thaw cycles that destabilize the peptide bonds.
PX1 Research is committed to supplying the scientific community with domestic, ultra-pure peptide reagents. Unlike vendors operating without standard quality control protocols, all PX1 compounds are synthesized in state-of-the-art, GMP-compliant US facilities.
We understand that research timelines demand fast, reliable delivery. Orders ship same-day (Monday through Friday) directly from our strategically located fulfillment centers in California and Arizona. Each shipment includes protective temperature-controlled packaging to preserve peptide integrity throughout transit.
When purchasing your CJC-1295 & Ipamorelin research compounds from PX1 Research, you gain access to consistent batch chemistry, transparent analytical verification, and dedicated support tailored to institutional and private research laboratories.
What is the function of the CJC-1295 & Ipamorelin blend in preclinical research?
The blend combines a long-acting GHRH analog (CJC-1295 No DAC) with a selective ghrelin receptor agonist (Ipamorelin). In preclinical models, this combination produces a synergistic elevation of endogenous growth hormone (GH) secretion and downstream IGF-1 levels without significantly altering ACTH or cortisol.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) maleimide moiety. Consequently, it has a plasma half-life of approximately 30 minutes, producing natural, pulsatile GH release. CJC-1295 with DAC binds to serum albumin, extending its half-life to several days and producing continuous baseline GH elevation.
Why are GHRH and GHRP compounds combined in a single research formulation?
Combining GHRH analogs and GH secretagogues activates two distinct intracellular signaling pathways (cAMP/PKA and PLC/IP3/Ca2+) on pituitary somatotrophs while attenuating somatostatin inhibition. Preclinical studies demonstrate that dual activation yields significantly higher peak GH amplitude than either agent administered alone.
What quality verification standards does PX1 Research provide with this blend?
Every lot of CJC-1295 & Ipamorelin blend undergoes independent third-party testing in an ISO 17025 accredited laboratory. Testing includes RP-HPLC for sequence purity (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for mass verification, and LAL testing to confirm low endotoxin levels (<0.01 EU/mg).
What solvent is recommended for reconstituting the blend for in vitro assays?
For routine laboratory preparation, Bacteriostatic Water containing 0.9% benzyl alcohol is typically utilized to prevent microbial growth during multi-dose sampling. For specific cell culture or sensitive in vitro assays where benzyl alcohol may interfere with viability, sterile 0.9% sodium chloride or sterile water for injection is recommended.
How should reconstituted CJC-1295 & Ipamorelin solutions be stored?
Reconstituted solutions must be kept refrigerated at 2°C to 8°C and protected from light. If prepared with bacteriostatic water, the solution remains stable for up to 30 days under refrigeration. Avoid repeated freeze-thaw cycles by preparing single-use aliquots if long-term storage is required.
Where does PX1 Research ship CJC-1295 & Ipamorelin blend orders from?
All orders are fulfilled from our US-based distribution centers located in California and Arizona. Orders placed Monday through Friday ship same-day to minimize transit times for laboratory researchers.
Is the CJC-1295 & Ipamorelin blend suitable for human consumption or therapy?
No. All products sold by PX1 Research, including the CJC-1295 & Ipamorelin blend, are strictly for laboratory research, in vitro experimentation, and preclinical research use only. They are not intended for human or animal therapeutic, diagnostic, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.